On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders. Stockholders approved an amendment to the 2020 Employee Stock Purchase Plan (ESPP) that reserves an additional 500,000 shares for issuance and eliminates the "evergreen" provision, which previously provided for automatic annual increases to the share reserve through 2030. The company also elected two Class III directors, Bridget Martell and Carole Nuechterlein, ratified Ernst & Young LLP as its independent auditor, and determined that future advisory votes on executive compensation will occur annually. Aligos Therapeutics is a biopharmaceutical company that develops therapeutic candidates for chronic liver diseases.